Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Chimerix, Inc. - Common Stock
(NQ:
CMRX
)
8.540
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Chimerix, Inc. - Common Stock
< Previous
1
2
3
Next >
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology
July 28, 2025
Via
Investor Brand Network
Topics
Artificial Intelligence
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
March 21, 2025
From
Chimerix, Inc.
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of Shareholders
March 12, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
March 11, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA on Behalf of Shareholders
March 11, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
March 10, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VOXX, CMRX, WBA, ML on Behalf of Shareholders
March 08, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2025
From
Chimerix, Inc.
Via
GlobeNewswire
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
March 07, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, IVAC, BRDG on Behalf of Shareholders
March 05, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Chimerix, Inc. (Nasdaq - CMRX), Siyata Mobile Inc. (Nasdaq - SYTA), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Intevac, Inc. (Nasdaq - IVAC)
March 05, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
March 05, 2025
From
Halper Sadeh LLC
Via
Business Wire
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
March 05, 2025
From
Chimerix, Inc.; Jazz Pharmaceuticals plc
Via
GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 18, 2025
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma
February 18, 2025
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium
January 29, 2025
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 24, 2025
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Speak Today at The White House Cancer Moonshot Forum
January 13, 2025
Chief Scientific Officer, Joshua E. Allen, Ph.D. to Highlight Cancer Moonshot’s Impact on Brain Cancer and Rare Pediatric Disease Drug Development
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
December 30, 2024
Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
December 09, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
November 11, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
November 07, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
November 01, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 30, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
August 13, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
August 06, 2024
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END
Via
FinancialNewsMedia
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
